CELU.US Celularity Inc

Healthcare Biotechnology USA Stocks
0.6301 USD
Close of Nov 14, 2026
0.5601 2.55
Market cap
USD 20.4M
P/E
-
P/B
9.89x
ROE
-
Dividend yield
28.85%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CELU.US undervalued?

Graham number

The Graham number of Celularity Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Celularity Inc fundamental analysis

No fundamental analysis for Celularity Inc yet.

Celularity Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Celularity Inc

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimm…

Full company profile